+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rare Biomarkers Specimen Collection and Stabilization - Global Strategic Business Report

  • PDF Icon

    Report

  • 88 Pages
  • May 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5304090
The global market for Rare Biomarkers Specimen Collection and Stabilization is estimated at US$42.5 Billion in 2023 and is projected to reach US$78.6 Billion by 2030, growing at a CAGR of 9.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Circulating Cell Free DNA (ccfDNA) segment, which is expected to reach US$30.8 Billion by 2030 with a CAGR of a 8.5%. The Circulating Tumor Cells (CTCs) segment is also set to grow at 9.6% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $13.1 Billion in 2023, and China, forecasted to grow at an impressive 8.5% CAGR to reach $13.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Rare Biomarkers Specimen Collection and Stabilization Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Rare Biomarkers Specimen Collection and Stabilization Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Rare Biomarkers Specimen Collection and Stabilization Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Advanced Cell Diagnostics, Inc., Agena Bioscience, ANGLE plc, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 32 Featured):

  • Advanced Cell Diagnostics, Inc.
  • Agena Bioscience
  • ANGLE plc
  • ApoCell, Inc.
  • AS One InternationalNTERNATIONAL
  • BioChain Institute, Inc.
  • Biolidics Limited
  • Biomatrica
  • Bio-Techne Corporation
  • BioVision, Inc.
  • Caltag Medsystems Limited
  • Cytomark Ltd.
  • DNA Genotek, Inc.
  • Epic Sciences
  • EpiGentek Group Inc.
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences, Inc.
  • Geno Technology Inc.
  • Genomax Technologies Pte Ltd.
  • GILUPI GmbH
  • LifeSpan BioSciences, Inc.
  • MagBio Genomics Inc.
  • Menarini Silicon Biosystems
  • MyBioSource.com
  • Norgen Biotek Corp.
  • Novus Biologicals, LLC
  • OraSure Technologies Inc.
  • Precision for Medicine, Inc.
  • Promega Corporation
  • QIAGEN
  • Rarecells Diagnostics SAS
  • RareCyte, Inc.
  • siemens Healthineers
  • SiO2 Materials Science
  • STEMCELL Technologies Inc.
  • Streck, Inc.
  • Thermo Fisher Scientific, Inc.
  • Vortex Biosciences
  • VyCAP B.V.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Rare Biomarkers Specimen Collection and Stabilization - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Circulating Cell Free DNA (ccfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 4: World 7-Year Perspective for Circulating Cell Free DNA (ccfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World 7-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Exosomes / Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World 7-Year Perspective for Exosomes / Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 10: World 7-Year Perspective for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 15: World Rare Biomarkers Specimen Collection and Stabilization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 16: USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 17: USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 18: USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 19: USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 22: Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 23: Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
JAPAN
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 24: Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 25: Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 26: Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
CHINA
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 28: China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 29: China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 30: China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 31: China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
EUROPE
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • Table 34: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 35: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 36: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 37: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
FRANCE
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 38: France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 40: France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 41: France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
GERMANY
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 42: Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 43: Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 44: Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
ITALY
  • Table 46: Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 47: Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 48: Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 49: Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
UNITED KINGDOM
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 50: UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 52: UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 53: UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
REST OF EUROPE
  • Table 54: Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 55: Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
ASIA-PACIFIC
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 58: Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 59: Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 60: Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 61: Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
REST OF WORLD
  • Table 62: Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • Table 64: Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 65: Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Advanced Cell Diagnostics, Inc.
  • Agena Bioscience
  • ANGLE plc
  • ApoCell, Inc.
  • AS One InternationalNTERNATIONAL
  • BioChain Institute, Inc.
  • Biolidics Limited
  • Biomatrica
  • Bio-Techne Corporation
  • BioVision, Inc.
  • Caltag Medsystems Limited
  • Cytomark Ltd.
  • DNA Genotek, Inc.
  • Epic Sciences
  • EpiGentek Group Inc.
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences, Inc.
  • Geno Technology Inc.
  • Genomax Technologies Pte Ltd.
  • GILUPI GmbH
  • LifeSpan BioSciences, Inc.
  • MagBio Genomics Inc.
  • Menarini Silicon Biosystems
  • MyBioSource.com
  • Norgen Biotek Corp.
  • Novus Biologicals, LLC
  • OraSure Technologies Inc.
  • Precision for Medicine, Inc.
  • Promega Corporation
  • QIAGEN
  • Rarecells Diagnostics SAS
  • RareCyte, Inc.
  • siemens Healthineers
  • SiO2 Materials Science
  • STEMCELL Technologies Inc.
  • Streck, Inc.
  • Thermo Fisher Scientific, Inc.
  • Vortex Biosciences
  • VyCAP B.V.

Table Information